**Core tip:** Use of the popular 5:2 intermittent energy restriction diet in people with type 2 diabetes requires careful manipulation of oral hypoglycemic agents and insulin to prevent poor blood glucose control. This short review fills a very important gap in the literature, reviewing necessary medication changes required in severe energy restriction and outlining how these changes may apply during the 5:2 diet by sharing our experiences from our recent 5:2 pilot trial.

INTRODUCTION
============

Approximately 80% of people with type 2 diabetes mellitus (T2DM) are overweight or obese\[[@B1]\]. Weight loss is known to reduce glycemia and increase insulin sensitivity\[[@B1]\] and large amounts of weight loss can lead to remission of T2DM\[[@B2]\]. However, weight loss for this population group is often difficult\[[@B3]\], with poor adherence to weight loss programs, suggesting people find continuous energy restriction (CER) difficult to maintain. Recently attention has been given to a new method of weight loss, known as intermittent energy restriction (IER), which in the overweight and obese populations, without diabetes, has shown to be comparable to CER in achieving weight loss\[[@B4],[@B5]\]. IER uses short periods (usually 2 d) of severe energy restriction, 400-800 kcal/d, followed by longer periods of habitual diet. There are however, very few studies comparing the effects of IER to daily CER in T2DM. Therefore, we have limited information on how to manage diabetes medications to prevent hypoglycemia, which is likely to occur during the short periods of severe energy restriction. We evaluated continuous very low calorie diet (VLCD) trials to provide a starting point for medication management and to provide guidance to future IER weight loss trials for people with T2DM.

MATERIALS AND METHODS
=====================

A search was conducted in MEDLINE, EMBASE, AMED, CINAHL and Cochrane library for original research articles investigating the use of VLCD in people with T2DM. The search terms used included "VLCD" or "very low energy diet" or "very low energy restriction" or "IER" or "intermittent fasting" or "calorie restriction" or "diabetes mellitus type 2" and "type 2 diabetes". Reference lists of selected articles were also screened for relevant publications. Only research articles written in English, which also included an explanation of medication changes were included.

VLCDs are defined as diets with an energy intake of \< 800 kcal (\< 3344 kJ) per day with at least 50 g of high-quality protein, essential fatty acids, daily requirements of vitamins and minerals as well as the addition of approximately 2 cups of non-starchy vegetables to prevent constipation. VLCDs can be given as a complete liquid formula or if food-based diets are used they often include a multivitamin supplement\[[@B6]\].

RESULTS
=======

Seven trials using continuous VLCD in participants with T2DM were found, and one controlled trial was found using intermittent VLCD (Table [1](#T1){ref-type="table"}). In six trials, including the intermittent VLCD trial, all oral hypoglycemic agents (OHA) were discontinued before the start of the trial\[[@B2],[@B7]-[@B11]\] regardless of the degree of glycemic control. In two trials, medications were reinitiated if blood glucose levels (BGL) were above a pre-determined level\[[@B7],[@B9]\]. In one trial, medications, including insulin, were restarted if the mean of two weekly fasting BGL averaged \> 13.3 mmol/L for two weeks, dosages were increased thereafter on a case-by-case basis\[[@B7]\]. In the second trial, medications were reinitiated at half the original dose if fasting BGLs increased \> 13.9 mmol/L\[[@B9]\]. In the other four trials, there was no mention of reinitiating medications\[[@B2],[@B8],[@B10],[@B11]\].

###### 

Summary of trials

  **Ref**.                   **Design**                  **Duration**           **Subjects**                                                                      **Aim**                                                                                                                                   **Diet groups**                                                                                                                                                     **Medication protocol**
  -------------------------- --------------------------- ---------------------- --------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Wing et al\[[@B7]\]        Randomized parallel study   50 wk 1-yr follow-up   *n* = 93 Male/female: 33/60 Mean age: 51.8 ± 9.7 Mean diagnosis (yr): 6.8 ± 6.1   Effects of a weight control program, with and without 2 × 12-wk VLCD restriction                                                          VLCD = 400-500 kcal *via* liquid or food-based diet from 1-12 wk and from 24-36 wk. LCD was followed at all other times LCD = 1000-1200 kcal                        All medications (inc. insulin) were discontinued at the start of the trial. Insulin was discontinued and monitored for 3 d. Dosages of oral medications or insulin were reinstated if the mean of two fasting blood glucose levels averaged \> 13.3 mmol/L over a fortnight. Dosages increased on a case-by-case basis
  Kelley et al\[[@B8]\]      Single arm study            24 wk                  *n* = 7 Male/female: 2/5 Mean age: 59 Mean diagnosis (yr): N/A                    Evaluating the efficacy of VLCD treatment in obese T2DM participants                                                                      VLCD = 400-800 kcal *via* liquid and food-based diet                                                                                                                Discontinued all oral glycemic medication 3 wk before commencement on the VLCD
  Williams et al\[[@B9]\]    Randomized parallel study   20 wk                  *n* = 54 Male/female: 23/31 Mean age: 51.9 ± 7.8 Mean diagnosis (yr): N/A         Evaluating the efficacy of intermittent VLCD restriction on weight loss and glycemic control compared to moderate calorie restriction     VLCD = 400-600 kcal *via* food-based diet. LDC (1500-1800 kcals) at all other times 2 groups: 1-d: 1 d/wk plus 5 consecutive days in week 2 5-d: 5 d/wk for 15 wk   Discontinued all oral glycemic medication 2 wk before the trial and people with fasting glucose \> 16.7 mmol/L were excluded. People using insulin were also excluded Medications were only reinstated if fasting BGLs (measured twice weekly) increased \> 13.9 mmol/L. Restarted medication occurred at half of the original dose
  Uusitupa et al\[[@B10]\]   Single arm study            12 wk                  *n* = 10 Male/female: 6/4 Mean age: 51 ± 2.2 Diagnosis (yr): Ranged 4-16          Evaluating the effects of weight loss using a VLCD on metabolic control and cardiovascular risk factors in obese participants with T2DM   VLCD = 500-800 kcals *via* liquid and food-based diet                                                                                                               Discontinued all oral glycemic medications before the start of the trial

VLCD: Very low calorie diet; LCD: Low calorie diet; T2DM: Type 2 diabetes mellitus; BGL: Blood glucose levels.

In the two remaining trials, diabetic medications and insulin were reduced by 50% at either the commencement of the VLCD treatment\[[@B12]\] or in accordance with self-monitored BGLs\[[@B13]\]. In one trial, participants measured fasting and postprandial BGLs daily for two days before the start of the VLCD and if the mean result was \< 8 and \< 10 mmol/L, respectively, diabetic medications were halved\[[@B13]\]. Conversely, if levels were \> 9 and \> 11 mmol/L, respectively, medications were increased\[[@B13]\]. Medication changes occurred in the following order; insulin was decreased first followed by sulfonylureas and lastly metformin, and when increasing, medications were increased in reverse order\[[@B13]\]. In the second trial, medications were halved at the initiation of the VLCD and reduced further if the fasting weekly average was \< 8.4 mmol/L or if participants experienced hypoglycemia (\< 3.4 mmol/L) and increased if fasting weekly BGLs averaged \> 8.4 mmol/L\[[@B12]\]. All changes to dosages occurred on a case-by-case basis in both trials\[[@B12],[@B13]\].

One trial used a VLCD in an overweight population with T2DM on an intermittent basis. The severe energy restriction was used at a frequency of either 1 d or 5 d per week over 20 wk. Oral glycemic agents were discontinued 2 wk before the start of the trial and people with fasting glucose \> 16.7 mmol/L were excluded. People using insulin were also excluded from this trial. Medication was reinstated, at half the original dose, if fasting BGLs increased to \> 13.9 mmol/L; participants were only required to measure their fasting BGLs levels twice per week.

We recently conducted a 3-mo pilot trial testing the effects of a 2-d IER compared to a CER diet in people with T2DM\[[@B14]\]. Our pilot trial demonstrated that 2 d of IER compared to CER achieves similar reductions in HbA1c (-0.7% ± 0.9%; *P* \< 0.001) and weight loss (-5.8± 3.9 kg; *P* \< 0.001)\[[@B14]\]. In the pilot trial, our protocol was to discontinue OHA likely to cause hypoglycemia (*e.g*., sulfonylureas) at baseline if HbA1c was \< 8%. Medications such as metformin, gliptins, and SGLT2 inhibitors remained unchanged. Participants using insulin were also asked to reduce their dose by 10 units/d if randomized to the CER group or halved on the IER days. If HbA1c was \> 8% at baseline OHA remained the same and insulin dose was decreased by 5-10 units on IER days. However, due to low BGLs in some participants we changed the medication protocol in preparation for our 12-mo intervention trial, which is currently ongoing. The new protocol requires discontinuation of sulfonylureas as well as insulin if baseline HbA1c is \< 7% for both groups. If HbA1c is \> 7% but \< 10% then medications are discontinued only on IER days and if HbA1c is \> 10% medications remain unchanged. Following this change, there has been a reduction in hypoglycemic events for participants taking insulin on IER days and a reduction in hyperglycemic events on non-IER days and in the CER group. It is important to note that in addition to changes made based on baseline values, it is also essential to monitor daily BGLs. Each participant requires individual medication changes, especially to insulin units, in response to weight loss.

DISCUSSION
==========

IER is an alternative method to achieve weight loss, which can be used for the management of T2DM. Due to the severe energy restriction required for IER diets to be effective, management of OHA, as well as insulin, requires constant supervision as well as ongoing blood glucose monitoring by the participant to prevent unwanted hypo- or hyperglycemic events. Medication changes will differ depending on the number of days the intermittent restriction is followed and is likely to only require intervention on these days unless glycemic control is excellent. The treatment method promoted by popular media suggests 2 d of restriction. We tested this method and we suggest baseline medication changes based on HbA1c, as outlined in the second protocol above, as well as individual changes in response to weight loss. Participants, therefore, need to be willing to monitor their BGLs at least twice daily and report any episodes of hypo- or hyperglycemia, which would indicate the need to further adjust medications.
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COMMENTS
========

Background
----------

Recently attention has been given to a new method of weight loss, known as intermittent energy restriction (IER), which has demonstrated positive results for weight loss in overweight and obese populations.

Research frontiers
------------------

For this new diet method to be used safely in the type 2 diabetes mellitus (T2DM) population, medication management protocol must be established.

Innovations and breakthroughs
-----------------------------

Very low calorie diets used in the treatment of T2DM provide insight, but as seen from the research, medication changes may only be required on the IER treatment days and after weight loss.

Applications
------------

IER is a successful treatment method for weight loss and glycemic control in T2DM, and with regular blood glucose levels monitoring, medications can be safely adjusted to limit unwanted episodes of hypo-or hyperglycemia.

Peer-review
-----------

The review though very short is written well. The authors state that intermittent energy restriction which requires severe energy restriction needs to be discussed as it is a developing concept.
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